December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
A Novel, Sustained-release Drug Delivery Device for Localised 'Beneath-the-flap' Steroids in Phaco-trabeculectomy
Author Affiliations & Notes
  • SL Seah
    Glaucoma Singapore National Eye Centre Singapore Singapore
  • G Gazzard
    Institute of Ophthalmology London United Kingdom
  • ST Hoh
    Glaucoma Singapore National Eye Centre Singapore Singapore
  • DT H Tan
    Ophthalmology National University Singapore Singapore
  • F Oen
    Glaucoma Singapore National Eye Centre Singapore Singapore
  • Footnotes
    Commercial Relationships   S.L. Seah, None; G. Gazzard, None; S.T. Hoh, None; D.T.H. Tan, None; F. Oen, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3346. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SL Seah, G Gazzard, ST Hoh, DT H Tan, F Oen; A Novel, Sustained-release Drug Delivery Device for Localised 'Beneath-the-flap' Steroids in Phaco-trabeculectomy . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3346.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To assess the initial safety and tolerability of an intra-scleral slow-release steroid pellet - SurodexTM, (Oculex Pharmaceuticals Inc.) for combined phaco-trabeculectomy. Methods: Patients undergoing primary combined (separate site) phacoemulsification and trabeculectomy for primary glaucoma received a single sustained release dexamethasone pellet (SurodexTM) placed beneath the standard scleral flap at the end of surgery, in addition to topical steroid and antibiotic. Full ophthalmic examination was conducted at baseline and follow-up. Standard interventions of massage, laser suturelysis and bleb needling (+/- 5FU) were permitted if necessary. This initial 'in-principle' study was designed to evaluate safety and monitor pellet dissolution in vivo using ultrasound biomicroscopy (UBM). Out of 70 Asian subjects enrolled, 16 Chinese patients who have reached 2 months follow-up are presented here (mean 67.4 days, range 60-106). Mean age 65.0 years (44 - 83). Results: No significant complications, adverse drug reactions or surgical failures were seen during follow-up. 11 patients received posterior lip flap massage, 12 required suturelysis and 5 ultimately received bleb needling, with 4 receiving 5FU. Bleb morphology was diffuse and non-cystic, with no avascular areas. The intra-ocular pressure was significantly reduced from a baseline mean of 27.8 mm Hg (+/- 6.7 SD) to 15.8 mm Hg (+/- 5.0 SD) at last follow-up, p < 0.001 (paired T Test). Surodex pellets were visible on UBM as a high signal-density intra-scleral area with prominent shadowing. Complete dissolution of the pellet on UBM took up to 4 weeks. Conclusion: Localised sustained-release steroid delivery by a biodegradable spacer device appears to be a safe and simple means to deliver steroids to the intrascleral site. A separate randomised controlled trial will investigate the efficacy of long-term pressure control.

Keywords: 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 631 wound healing 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.